Gefapixant effective treatment for unexplained chronic cough: Lancet

Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-04-13 04:45 GMT   |   Update On 2022-04-13 06:53 GMT
Advertisement

A phase 3 clinical study conducted by Prof Lorcan P McGarvey and team has revealed that for refractory chronic cough or unexplained chronic cough, gefapixant 45 mg twice a day was the first medication to show effectiveness with an acceptable safety profile. The findings of this study were published in The Lancet.

Gefapixant, which is an oral P2X3 receptor antagonist has previously been found to be effective and safe in the treatment of refractory chronic cough and unexplained chronic cough. As a result, the purpose of this study was to confirm the effectiveness and safety of gefapixant in patients with unexplained chronic cough and refractory chronic cough.

Advertisement

COUGH-1 and COUGH-2 were both phase 3 studies that were double-blind, randomized, parallel-group, placebo-controlled. COUGH-1 was carried out in 156 locations across 17 nations, whereas COUGH-2 was carried out in 175 sites across 20 countries. Participants in this research had to be 18 years old or older and have a diagnosis of refractory chronic cough or unexplained chronic cough for at least a year. Participants had to have a cough intensity visual analogue scale score of 40 mm or above at both screening and baseline. Using a computer-generated allocation schedule, eligible individuals were randomly assigned (1:1:1) to one of three treatments: placebo, gefapixant 15 mg twice per day, or gefapixant 45 mg twice per day. All research medications were administered orally. The primary outcome in COUGH-1 was the placebo-adjusted mean change in 24-hour cough frequency after 12 weeks and 24 weeks in COUGH-2.

The findings were as follow:

1. Gefapixant 45 mg twice daily reduced the 24-hour cough frequency significantly more than placebo at week 12 in COUGH-1 and week 24 in COUGH-2.

2. In all investigations, gefapixant 15 mg twice a day did not show a significant reduction in cough frequency when compared to placebo.

3. Ageusia, dysgeusia, hypergeusia, hypogeusia, and taste abnormality were the most prevalent adverse events associated with taste disturbance.

In conclusion, gefapixant dosage assessment twice per day shows significant positive effect and in future this treatment should be considered very often for any unexplained chronic cough.

Reference: 

McGarvey, L. P., Birring, S. S., Morice, A. H., Dicpinigaitis, P. V., Pavord, I. D., Schelfhout, J., Nguyen, A. M., Li, Q., Tzontcheva, A., Iskold, B., Green, S. A., Rosa, C. L., Muccino, D. R., & Smith, J. A. (2022). Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. In The Lancet (Vol. 399, Issue 10328, pp. 909–923). Elsevier BV. https://doi.org/10.1016/s0140-6736(21)02348-5

Tags:    
Article Source : The Lancet

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News